Ernesto Durini
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 10%
- Hepatology top 5%
- Surgery
- Pathology and Forensic Medicine
- Co-authors
- Vittorio GebbiaGiuseppe PezzellaMichele CarusoBiagio AgostaraNicola BorsellinoNicola GebbiaS. RomitoMassimo Lopez
- Topics
- Cancer Treatment and Pharmacology (8 papers)Lung Cancer Treatments and Mutations (7 papers)Lung Cancer Research Studies (5 papers)
- Partner nations
- ItalyJapanUnited States
In The Last Decade
Ernesto Durini
14 papers receiving 701 citations
Hit Papers
Peers
Comparison fields: 5 of 63
- Oncology 629
- Pulmonary and Respiratory Medicine 277
- Hepatology 222
- Surgery 117
- Pathology and Forensic Medicine 92
Countries citing papers authored by Ernesto Durini
This map shows the geographic impact of Ernesto Durini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernesto Durini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernesto Durini more than expected).
Fields of papers citing papers by Ernesto Durini
This network shows the impact of papers produced by Ernesto Durini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernesto Durini. The network helps show where Ernesto Durini may publish in the future.
Co-authorship network of co-authors of Ernesto Durini
This figure shows the co-authorship network connecting the top 25 collaborators of Ernesto Durini. A scholar is included among the top collaborators of Ernesto Durini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernesto Durini. Ernesto Durini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 32 | |
| 2 | Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionalebreakdown → | 586 |
| 3 | 5 | |
| 4 | 16 | |
| 5 | 20 | |
| 6 | 33 | |
| 7 | 3 | |
| 8 | Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma. | 11 |
| 9 | 1 | |
| 10 | 4 | |
| 11 | 4 | |
| 12 | 5 | |
| 13 | 8 | |
| 14 | Cyclophosphamide, mitoxantrone and fluorouracil versus cyclophosphamide, mitoxantrone and fluorouracil plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical trial | 4 |
About Ernesto Durini
Ernesto Durini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Dermatology, having authored 14 papers that have together received 732 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Research Studies (5 papers). The work is most often cited by research in Hepatology (222 citations), Oncology (629 citations) and Pulmonary and Respiratory Medicine (277 citations). Ernesto Durini has collaborated with scholars based in Italy, Japan and United States. Frequent co-authors include Vittorio Gebbia, Giuseppe Pezzella, Michele Caruso, Biagio Agostara, Nicola Borsellino, Nicola Gebbia, S. Romito, Massimo Lopez, Giuseppe Colucci and Stefano Cordio. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.